Ravikanth Vishnubhotla

Ravikanth Vishnubhotla

Auto-generated profile, based on publicly available information

Ravikanth Vishnubhotla

Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad 500032, Telangana, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
GBGovardhan Bale
Govardhan Bale
RVRavikanth V. Vishnubhotla
Ravikanth V. Vishnubhotla
SMSasikala Mitnala
Sasikala Mitnala
MSMithun Sharma
Mithun Sharma
RPRao N. Padaki
Rao N. Padaki
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur

1 September 2016 in Meta Gene
Verified
Journal Article
Open access
NDNeha Deshpande
Neha Deshpande
SVSharanya V.
Sharanya V.
RVRavi Kanth V. V.
Ravi Kanth V. V.
MVMurthy H. V. V.
Murthy H. V. V.
SMSasikala M.
Sasikala M.
NDNageshwar Reddy D.
Nageshwar Reddy D.
Polymorphisms in genes encoding drug metabolizing enzymes may lead to varied enzyme activity and inter-individual variability in drug efficacy and/or toxicity. Since CYP2C19 and CYP3A4 genes code for enzymes involved in metabolizing wide variety of drugs including proton pump inhibitors, we sought to identify polymorphisms in these genes in order to study their impact on drug metabolism in subjects. DNA was isolated from healthy individuals including tribals and genotyped for 11 single nucleotide polymorphisms in CYP2C19 and 6 polymorphisms in CYP3A4. Individuals were categorized into different phenotypes based on their drug metabolizing genotype. Volunteers from each group were administered proton pump inhibitors (Esomeprazole, Pantoprazole; 40 mg/day) for 5 days followed by pharmacokinetic studies and measurement of intra-gastric pH. Of the 17 polymorphisms studied, only CYP2C19*2,*3,*17 and CYP3A4*1B polymorphisms were observed. In comparison to urban individuals, a significantly (p = 0.0003) higher number of poor metabolizers were noted in the tribal individuals. Pantoprazole was found to be most effective in poor metabolizers in terms of area under the curve and Tmax. No significant difference was observed in the intra-gastric pH at baseline and day 6 in rapid and ultra-rapid metabolizers. Our study has demonstrated that 19.7% of our subjects are carriers of the CYP2C19*17 allele who did not respond to the standard dose of proton pump inhibitors. Genetic screening to identify subjects with variant alleles would thus be useful for personalization of therapy with proton pump inhibitors.

21 July 2021 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
RVRavikanth Vishnubhotla
Ravikanth Vishnubhotla
SMSasikala Mitnala
Sasikala Mitnala
VKVijayasarathy Ketavarapu
Vijayasarathy Ketavarapu
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur
Introduction: Human leukocyte antigen (HLA) variability has been demonstrated to be associated with susceptibility/severity of COVID‐19. High‐resolution HLA genotyping to identify alleles associated with severe COVID‐19 in an Indian cohort was performed.Methods: Quantitative reverse‐transcription polymerase chain reaction‐confirmed SARS‐CoV‐2‐positive patients with mild/moderate/severe disease (n = 54) and asymptomatic (n = 42) were recruited and genotyped for 11‐HLA loci on MiSeq using NGSgo®‐MX11‐3 and analyzed (NGSengine; GenDx).Results: A significant difference in alleles between the groups was identified for HLA‐C*04:01:01:01, HLA‐DRB5*01:01:01:02, HLA‐DQA1*03:01:01:01, HLA‐DPB1*04:01:01:41, and HLA‐DPA1*01:03:01:02. Alleles namely, HLA‐C*04:01:01:01 (OR: 5.71; 95% CI: 1.2–27.14; p = .02), HLA‐DRB5*01:01:01:02 (OR: 2.94; 95% CI: 1.1–7.84; p = .03), DQA1*03:01:01:01 (OR: 22.47; 95% CI: 1.28–393.5; p = .03), HLA‐DPB1*04:01:01:41 (OR: 9.44; 95% CI: 0.5–175.81; p = .13), and HLA‐DPA1*01:03:01:02 (OR: 8.27; 95% CI: 2.26–30.21; p = .001) were associated with severe COVID‐19.Conclusion: Genotyping for these alleles will enable identification of individuals at risk of severe disease and stratification for preferential vaccination.

3 January 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
ZNZaheer Nabi
Zaheer Nabi
RTRupjyoti Talukdar
Rupjyoti Talukdar
RVRavikanth Venkata
Ravikanth Venkata
MAMohsin Aslam
Mohsin Aslam
USUpender Shava
Upender Shava
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur

1 September 2016 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
VRVishnubhotla Venkata Ravikanth
Vishnubhotla Venkata Ravikanth
GRGuduru Venkat Rao
Guduru Venkat Rao
BGBale Govardhan
Bale Govardhan
MSMitnala Sasikala
Mitnala Sasikala
CSChivukula Subramanyam
Chivukula Subramanyam
DRDuvvuru Nageshwar Reddy
Duvvuru Nageshwar Reddy

1 January 2018 in Indian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
UAUrmila Steffie Avanthi
Urmila Steffie Avanthi
GBGovardhan Bale
Govardhan Bale
MAMohsin Aslam
Mohsin Aslam
RTRupjyoti Talukdar
Rupjyoti Talukdar
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur
RVRavikanth Venkata Vishnubhotla
Ravikanth Venkata Vishnubhotla